Shots: Vaxelis a hexavalent combination vaccine is approved for the prevention of Diphtheria, Tetanus, Pertussis, Poliomyelitis, Hepatitis B and Haemophilus influenzae type B in children from 6 wks. to 4 […]readmore
Tags : Sanofi
Shots: The study involves assessing of Praluent (75mg & 150mg, q2w) vs PBO in patients with MACE events and experienced ACS between 1 to 12 mos. in 18,924 patients for […]readmore
Shots: Novo Nordisk lay off nearly 250 employees in US due to slow revenue growth, and they will hire undetermined numbers of new employees in new positions Genentech to […]readmore
Shots: Denali to get $125M upfront plus milestones payments that can exceed $1B and will also receive royalties for DNL747 (ex-US & China) & DNL758 (WW). The profit/loss sharing will […]readmore
Shots: Sanofi and Evotec launches BRIDGE LAB031, designed to convert academic research into drug discovery candidates for multiple therapeutic areas. BRIDGE is a public-private partnership combining academia, biotech and venture […]readmore
Shots: The approval is based on the results of P-II EMPOWER-CSCC-1 study and P-I study 1423 (two advanced CSCC expansion cohorts) assessing Libtayo in patients with mCSCC, locally advanced CSCC […]readmore
Shots: Results of P-III ODYSSEY OUTCOMES assessing PRALUENT(alirocumab) IV (N= 18,924), having an acute coronary syndrome (ACS), such as a heart attack, b/w 1-12 mos before being enrolled The US […]readmore
Shots: The approval is based on P-II TITAN and P-III HERCULES studies enrolling 220 adults assessing Cablivi (caplacizumab) vs PBO, testing its safety and efficacy P-III HERCULES results: significantly shorter […]readmore
Shots: Sanofi acquires Bioverativ, in all stock transaction with its Eloctate & Alprolix products. Bioverativ to receive $105/share in cash for a premium of 64 % with total deal value […]readmore